5-叔丁基呋喃-2-羧酸 | 56311-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-叔丁基呋喃-2-羧酸
• 英文名称: 5-tert-butylfuran-2-carboxylic acid
• 英文别名: 5-tert-butyl-furan-2-carboxylic acid；5-t-butyl-2-furoic acid；5-tert-butyl-2-furoic acid；5-tert-butyl-furan-2-carboxylic acid；5-tert-Butyl-furan-2-carbonsaeure
• CAS: 56311-39-8
• 化学式: C₉H₁₂O₃
• mdl: MFCD00094279
• 分子量: 168.192
• InChiKey: JWZMCIVGRRFEEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  5-叔丁基呋喃-2-羧酸 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成 3-azido-5-tert-butylfuran-2-carboxylic acid
  参考文献：
  名称：

  ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES

  摘要：

  公开号：

  EP1019040B1
• 作为产物：
  描述：

  5-叔丁基呋喃-2-羧酸甲酯 生成 5-叔丁基呋喃-2-羧酸
  参考文献：
  名称：

  MASAMUNE T.; ONO M.; MATSUE H., BULL. CHEM. SOC. JAP. , 1975, 48, NO 2, 491-496

  摘要：

  DOI：

文献信息

• PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US20190202801A1

  公开（公告）日：2019-07-04

  Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供了哌嗪氨基甲酸酯和包含该化合物的药物组合物。所述化合物和组合物可用作MAGL和/或ABHD6的调节剂。此外，所述化合物和组合物可用于治疗疼痛。
• Inhibition of p38 kinase activity by aryl ureas
  申请人：Bayer Corporation

  公开号：US06344476B1

  公开（公告）日：2002-02-05

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.

  本发明涉及一组芳香脲在治疗非癌症的细胞因子介导疾病和非癌症的蛋白水解酶介导疾病中的用途，以及用于此类治疗的药物组合物。
• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• One-step synthesis of 5-acylisothiazoles from furans
  作者：Jérôme Guillard、Christelle Lamazzi、Otto Meth-Cohn、Charles W. Rees、Andrew J. P. White、David J. Williams

  DOI：10.1039/b101157j

  日期：——

  Premixed ethyl carbamate, thionyl chloride and pyridine (which generate thiazyl chloride, NSCl) in boiling benzene or toluene convert 2,5- and 2,3,5-substituted furans into 5-acylisothiazoles regiospecifically. The reactions are much faster and generally higher yielding in boiling chlorobenzene with more thionyl chloride and with pyridine or isoquinoline as base. Under the more vigorous conditions, even fully substituted 3-bromofurans give isothiazoles, with the displacement of bromine. Deactivated furans, with electron-withdrawing groups such as ester, cyano, benzoyl and phenylsulfonyl in the α-position, react under the more vigorous conditions to give 5-acylisothiazoles with the electronegative group in the 3-position. The ‘activated’ 2-methyl-5-phenyl- and 5-phenyl-2-phenylthio-furans react analogously, with the more electron-releasing group becoming part of the 5-acyl substituent, exclusively or predominantly. These results are explained by initial electrophilic attack of the furan ring to give a β-thiazyl derivative which spontaneously ring-opens and closes to the isothiazole. The X-ray structures of five of the differently substituted isothiazole compounds are reported. All have very similar patterns of bonding within their isothiazole rings that appear to be independent of the electron-withdrawing or -donating nature of the substituents. Three of the compounds (8a, 8g and 13) have loosely linked chain structures in the solid state, adjacent molecules being connected by combinations of hydrogen bonding and π–π stacking interactions.

  预混的乙基氨基甲酸、亚硫酰氯和吡啶（生成噻唑氯，NSCl）在沸腾的苯或甲苯中能够进行区域特异性地将2,5-和2,3,5-取代的呋喃转化为5-酰基异噻唑。在沸腾的氯苯中，反应更快，产率普遍更高，且使用了更多的亚硫酰氯及吡啶或异喹啉作为碱。在更激烈的反应条件下，甚至完全取代的3-溴呋喃也能与溴发生取代反应生成异噻唑。对于那些带有电子吸引基团（如酯、氰、苯甲酰和苯磺酰）且位于α位的非活性呋喃，在较为激烈的条件下也能反应，生成5-酰基异噻唑，其中电负性基团位于3位。这些“活化”型的2-甲基-5-苯基和5-苯基-2-苯硫基呋喃也表现出类似的反应，其中电子供给基团会独占或主导成为5-酰基取代基。其结果可以通过呋喃环的初始亲电攻击解释，生成β-噻唑衍生物，随后自发环打开并闭合成异噻唑。报告了五种不同取代异噻唑化合物的X射线结构，所有化合物在其异噻唑环内的键合模式非常相似，似乎与取代基的电子吸引或供给特性无关。三种化合物（8a、8g和13）在固态下具有松散联接的链结构，邻近的分子通过氢键和π–π堆叠相互作用相连。
• Inhibition of raf kinase activity using aryl ureas
  申请人：Onyx Pharmaceuticals

  公开号：US06187799B1

  公开（公告）日：2001-02-13

  Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

  利用替代脲化合物治疗由raf激酶介导的肿瘤的方法，以及这些化合物本身。